MLICM
MLYS icon

Metropolitan Life Insurance Company (MetLife)’s Mineralys Therapeutics MLYS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,238
Closed -$16K – 1288
2024
Q1 		$16K Hold
1,238
– – ﹤0.01% 1959
2023
Q4 		$10.6K Buy
1,238
+511
+70% +$4.01K ﹤0.01% 2159
2023
Q3 		$6.91K Hold
727
– – ﹤0.01% 2361
2023
Q2 		$12.4K Buy
+727
New +$10.9K ﹤0.01% 2184

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s MLYS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Mineralys Therapeutics (MLYS) in Q2 2024, closing a stake of 1,238 shares — an estimated $16K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in MLYS in Q2 2023 and held it in 4 quarters. The position peaked at $16K in Q1 2024. 94 funds tracked by Wall St. Rank hold MLYS as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Mineralys Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,238 Mineralys Therapeutics shares in Q2 2024, an estimated $16K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Mineralys Therapeutics in Q2 2023 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Mineralys Therapeutics position peaked at $16K in Q1 2024.
  • 94 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.